P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis
ECCO'20 Vienna
2020
P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
ECCO'20 Vienna
2020
P465 Therapeutic drug monitoring in Crohn’s disease patients, a comparison between homogeneous mobility shift assay and point of care method
ECCO'20 Vienna
2020
P466 Is it possible avoid colectomy with rescue dual therapy with vedolizumab plus tacrolimus in ulcerative colitis that losing response to anti-tumour necrosis factor?
ECCO'20 Vienna
2020
P467 Can induction and maintenance serum vedolizumab levels predict long-term clinical outcome in inflammatory bowel disease (IBD)?
ECCO'20 Vienna
2020
P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study
ECCO'20 Vienna
2020
P469 Stay in class or switch out of class after anti-TNF failure in inflammatory bowel disease (IBD). Real-world data from a large district general hospital
ECCO'20 Vienna
2020
P471 What is the appropriate cut-off value of CRP to predict endoscopic remission in ulcerative colitis patients with clinical remission?
ECCO'20 Vienna
2020
P472 Optimising the development of apps for the management of inflammatory bowel disease and participation in clinical trials
ECCO'20 Vienna
2020
P473 Long-term follow-up of switching from original adalimumab to adalimumab biosimilar: real-world data in IBD
ECCO'20 Vienna
2020
P475 Association between disease duration and degree of endoscopic improvement in patients with ulcerative colitis treated with tofacitinib
ECCO'20 Vienna
2020
P476 Efficacy and safety of 2 vedolizumab IV regimens in patients with perianal fistulising Crohn’s disease: results of the ENTERPRISE study
ECCO'20 Vienna
2020
P477 Italian real-life study evaluating the long-term effectiveness of vedolizumab for the treatment of inflammatory bowel disease: the elderly cohort
ECCO'20 Vienna
2020
P478 Thiopurines’ metabolites levels and drug toxicity: a systematic review and meta-analysis
ECCO'20 Vienna
2020
P479 The effect of adalimumab on linear growth in children with Crohn’s disease: a post hoc analysis of the PAILOT randomised control trial
ECCO'20 Vienna
2020